Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lung Diseases × Nivolumab × Clear all

Phase

Status

Sponsor Class

OTHER 4 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 119 Melanoma 112 Neoplasms 65 Carcinoma, Renal Cell 59 Colorectal Neoplasms 42 Neoplasm Metastasis 39 Squamous Cell Carcinoma of Head and Neck 36 Stomach Neoplasms 35 Carcinoma, Hepatocellular 32 Carcinoma, Transitional Cell 27 Lung Neoplasms 23 Pancreatic Neoplasms 21 Ovarian Neoplasms 21 Head and Neck Neoplasms 21 Triple Negative Breast Neoplasms 20 Advanced Cancer 19 Breast Neoplasms 17 Urinary Bladder Neoplasms 15 Small Cell Lung Carcinoma 14 Kidney Neoplasms 13 Recurrence 12 Hodgkin Disease 11 Uterine Cervical Neoplasms 10 Skin Neoplasms 10 Lymphoma 10 Solid Tumor 9 Endometrial Neoplasms 9 Carcinoma, Merkel Cell 9 Carcinoma 9 Adenocarcinoma Of Esophagus 9

Interventions

Carboplatin 9 Pemetrexed 7 pembrolizumab 4 osimertinib 3 entinostat 3 Gemcitabine 3 zipalertinib 2 selpercatinib 2 pralsetinib 2 durvalumab 2 camrelizumab 2 Paclitaxel 2 Erlotinib Hydrochloride 2 Cisplatin 2 Bronchoscopy 2 taletrectinib 1 sotorasib 1 repotrectinib 1 patritumab 1 necitumumab 1 ficlatuzumab 1 exemestane 1 demcizumab 1 cobimetinib 1 ceralasertib 1 atezolizumab 1 alectinib 1 aflibercept 1 Vinorelbine 1 Toll-Like Receptor 1 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡